GlassScriptPhysician profile
Kenya Neoko Singleton
NPI 1003901638
$5,472.32
in general payments reported to CMS, 2019-2025
28 companies · $1,293 in 2025
The $1,293 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $747 · 2022: $941 · 2023: $1,098 · 2024: $1,394 · 2025: $1,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,784.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $703.51 | 2021-2025 | |
| Edwards Lifesciences Corporation | $551.75 | 2021-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Astrazeneca Pharmaceuticals LP | $509.58 | 2021-2025 | Lokelma |
| Otsuka America Pharmaceutical, INC. | $351.66 | 2022-2024 | Rexulti |
| Abiomed | $278.16 | 2023-2024 | Impella |
| Lilly USA, LLC | $246.81 | 2024-2025 | Mounjaro, Kisunla |
| Alkermes, INC. | $244.89 | 2022-2025 | Lybalvi |
| Coloplast Corp | $161.41 | 2023 | Sensura Mio |
| Aspira Women'S Health INC | $151.84 | 2024 | Ova1 |
| Regeneron Pharmaceuticals, INC. | $149.98 | 2025 | Dupixent |
| Neurocrine Biosciences, INC. | $140.00 | 2022 | |
| Averitas Pharma INC. | $128.15 | 2024 | Qutenza |
| Hologic Sales and Service, LLC | $127.70 | 2024 | Aptima |
| Axsome Therapeutics, INC. | $124.99 | 2025 | Auvelity |
| Lundbeck LLC | $124.99 | 2024 | Vyepti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $124.99 | 2025 | Vascepa |
| Ucb, INC. | $124.97 | 2024 | Nayzilam |
| Janssen Pharmaceuticals, INC | $123.50 | 2022 | |
| Genentech USA, INC. | $123.50 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $122.62 | 2023 | Austedo Xr |
| Argenx US, INC. | $121.82 | 2023 | Vyvgart |
| Sanofi-Aventis U.S. LLC | $121.82 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $114.58 | 2024 | Arcalyst |
| Globus Medical, INC. | $114.34 | 2025 | Senza |
| E.R. Squibb & Sons, L.L.C. | $111.49 | 2024 | Reblozyl |
| Exact Sciences Corporation | $96.53 | 2023 | Cologuard Collection Kit |
| Hydrofera LLC | $91.41 | 2023 | Hydrofera Blue |
| Gilead Sciences, INC. | $85.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenya Singleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.